Current management of locally advanced rectal cancer achieves high cure rates, distant
metastatic spread being the main cause of patients' death. Total neoadjuvant therapy (TNT) …

Over the last two decades, the standard treatment for locally advanced rectal cancer (LARC)
has been neoadjuvant chemoradiotherapy plus total mesorectal excision followed by …

The multimodal approach with total mesorectal excision preceded by neoadjuvant (chemo)
radiotherapy represented the mainstay treatment for locally advanced rectal cancer (LARC) …

Colorectal cancer is the third most commonly occurring cancer worldwide and the second-
leading cause of cancer death. 1 Historically, the definitive management of rectal …

Simple Summary Locally advanced rectal cancer (LARC) is a group of highly
heterogeneous tumors. According to the European Society for Medical Oncology (ESMO) …

Although current guidelines on rectal cancer treatment often recommend rectal resection
with or without neoadjuvant (chemo) radiotherapy, there is growing interest in organ …

Aim Organ saving treatment for early-stage rectal cancer can reduce patient reported side
effects compared to standard total mesorectal excision (TME) and preserve quality of life …

Résumé La prise en charge du cancer du rectum a connu une avancée importante avec
l'apparition en 2021 du traitement néoadjuvant total. Les publications princeps des essais …

Purpose The standard treatment of T2–T3 rectal adenocarcinoma is radical proctectomy by
total mesorectal excision often combined with some neoadjuvant treatment. To reduce …

Abstract The American Society of Clinical Oncology annual meeting is the largest
multidisciplinary oncology-focused conference in the world. With almost 5000 total abstracts …